Full dose S-1 monotherapy compared to reduced dose S-1/oxaliplatin combination therapy as first-line treatment for older patients with metastatic colorectal cancer S1 eller S1/oxaliplatin

Trial Profile

Full dose S-1 monotherapy compared to reduced dose S-1/oxaliplatin combination therapy as first-line treatment for older patients with metastatic colorectal cancer S1 eller S1/oxaliplatin

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Bevacizumab; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms NORDIC9
  • Most Recent Events

    • 02 Jun 2017 Results of preplanned safety analysis (n=50) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 11 Oct 2016 Trial design is presented at 41st European Society for Medical Oncology Congress.
    • 01 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top